Drug intelligence / Profile preview

SPP1 inhibitor

Development stage: Preclinical
Lead developer: University of Kentucky
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SPP1 (osteopontin) inhibitors are therapeutic agents aimed at neutralizing the activity of Secreted Phosphoprotein 1 (SPP1), a multifunctional glycoprotein implicated in tumor progression and immune evasion. In gastric cancer, particularly peritoneal carcinomatosis, SPP1 is highly expressed and correlates with increased macrophage infiltration. Research presented at AACR 2026 indicates that the SPP1-IL10 axis serves as a critical crosstalk mechanism between cancer cells and macrophages. Targeted SPP1 blockade has demonstrated the ability to reprogram the tumor microenvironment by inhibiting macrophage trafficking and IL-10 secretion, leading to significant reductions in tumor weight and peritoneal nodule formation in preclinical syngeneic murine models.

Other names: osteopontin inhibitoranti-SPP1anti-SPP-1anti-SPP 1SPP1 blockadeSPP-1 blockadeSPP 1 blockade

Targets

SPP1 (Osteopontin)

Beyond the preview

Go deeper on SPP1 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPP1 inhibitor.

Explore the full profile